Constructing Immune and Prognostic Features Associated with ADCP in Hepatocellular Carcinoma and Pan-cancer Based on ScRNA-seq and Bulk RNA-seq

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 May 22

PMID 38774870

Authors

Zhengwei Zhang

Yuying Li

Zhen Quan

Yapeng Li

Liying Zhu

Shibo Sun

Xiaoning Chen

Affiliations

Soon will be listed here.

Abstract

Aim: Despite the significant therapeutic outcomes achieved in systemic treatments for liver hepatocellular carcinoma (LIHC), it is an objective reality that only a low proportion of patients exhibit an improved objective response rate (ORR) to current immunotherapies. Antibody-dependent cellular phagocytosis (ADCP) immunotherapy is considered the new engine for precision immunotherapy. Based on this, we aim to develop an ADCP-based LIHC risk stratification system and screen for relevant targets.

Method: Utilizing a combination of single-cell RNA sequencing (scRNA-seq) and bulk RNA-seq data, we screened for ADCP modulating factors in LIHC and identified differentially expressed genes along with their involved functional pathways. A risk scoring model was established by identifying ADCP-related genes with prognostic value through LASSO Cox regression analysis. The risk scoring model was then subjected to evaluations of immune infiltration and immunotherapy relevance, with pan-cancer analysis and experimental studies conducted on key targets.

Results: Building on the research by Kamber RA et al., we identified GYPA, CLDN18, and IRX5 as potential key target genes regulating ADCP in LIHC. These genes demonstrated significant correlations with immune infiltration cells, such as M1-type macrophages, and the effectiveness of immunotherapy in LIHC, as well as a close association with clinical pathological staging and patient prognosis. Pan-cancer analysis revealed that CLDN18 was prognostically and immunologically relevant across multiple types of cancer. Validation through tissue and cell samples confirmed that GYPA and CLDN18 were upregulated in liver cancer tissues and cells. Furthermore, knockdown of CLDN18 inhibited the malignancy capabilities of liver cancer cells.

Conclusion: We have identified an ADCP signature in LIHC comprising three genes. Analysis based on a risk scoring model derived from these three genes, coupled with subsequent experimental validation, confirmed the pivotal role of M1-type macrophages in ADCP within LIHC, establishing CLDN18 as a critical ADCP regulatory target in LIHC.

Citing Articles

Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets.

Guan F, Wang R, Yi Z, Luo P, Liu W, Xie Y Signal Transduct Target Ther. 2025; 10(1):93.

PMID: 40055311 PMC: 11889221. DOI: 10.1038/s41392-025-02124-y.

References

Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C . α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. Int J Cancer. 2023; 154(6):1043-1056. DOI: 10.1002/ijc.34799. View

Zhu L, Liu Y, Chen Q, Yu G, Chen J, Chen K . Long-Noncoding RNA Colorectal Neoplasia Differentially Expressed Gene as a Potential Target to Upregulate the Expression of IRX5 by miR-136-5P to Promote Oncogenic Properties in Hepatocellular Carcinoma. Cell Physiol Biochem. 2018; 50(6):2229-2248. DOI: 10.1159/000495084. View

Sewnath C, Behrens L, van Egmond M . Targeting myeloid cells with bispecific antibodies as novel immunotherapies of cancer. Expert Opin Biol Ther. 2022; 22(8):983-995. DOI: 10.1080/14712598.2022.2098675. View

Zhu L, Dai L, Yang N, Liu M, Ma S, Li C . Transcription factorIRX5 promotes hepatocellular carcinoma proliferation and inhibits apoptosis by regulating the p53 signalling pathway. Cell Biochem Funct. 2020; 38(5):621-629. PMC: 7384050. DOI: 10.1002/cbf.3517. View

Finn R, Ryoo B, Merle P, Kudo M, Bouattour M, Lim H . Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2019; 38(3):193-202. DOI: 10.1200/JCO.19.01307. View

Singal A, Kanwal F, Llovet J . Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol. 2023; 20(12):864-884. DOI: 10.1038/s41571-023-00825-3. View

Yu J, Li S, Chen D, Liu D, Guo H, Yang C . SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the "don't eat me" signal and activating the "eat me" signal. J Hematol Oncol. 2022; 15(1):167. PMC: 9670587. DOI: 10.1186/s13045-022-01385-2. View

An Z . "Magic Bullets" at the center stage of immune therapy: a special issue on therapeutic antibodies. Protein Cell. 2017; 9(1):1-2. PMC: 5777979. DOI: 10.1007/s13238-017-0488-1. View

Kamber R, Nishiga Y, Morton B, Banuelos A, Barkal A, Vences-Catalan F . Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis. Nature. 2021; 597(7877):549-554. PMC: 9419706. DOI: 10.1038/s41586-021-03879-4. View

10.

Argentiero A, Delvecchio A, Fasano R, Andriano A, Caradonna I, Memeo R . The Complexity of the Tumor Microenvironment in Hepatocellular Carcinoma and Emerging Therapeutic Developments. J Clin Med. 2023; 12(23). PMC: 10706931. DOI: 10.3390/jcm12237469. View

11.

Dutta A, Bhagat S, Paul S, Katz J, Sengupta D, Bhargava D . Neutrophils in Cancer and Potential Therapeutic Strategies Using Neutrophil-Derived Exosomes. Vaccines (Basel). 2023; 11(6). PMC: 10301170. DOI: 10.3390/vaccines11061028. View

12.

Wu J, Chan Y, Lu Y, Wang N, Feng Y . The tumor microenvironment in the postsurgical liver: Mechanisms and potential targets of postoperative recurrence in human hepatocellular carcinoma. Med Res Rev. 2023; 43(6):1946-1973. DOI: 10.1002/med.21967. View

13.

Li H, Somiya M, Kuroda S . Enhancing antibody-dependent cellular phagocytosis by Re-education of tumor-associated macrophages with resiquimod-encapsulated liposomes. Biomaterials. 2020; 268:120601. DOI: 10.1016/j.biomaterials.2020.120601. View

14.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

15.

Arulanandam A, Lin L, Chang H, Cerutti M, Choblet S, Gao P . Derivation and Preclinical Characterization of CYT-303, a Novel NKp46-NK Cell Engager Targeting GPC3. Cells. 2023; 12(7). PMC: 10093649. DOI: 10.3390/cells12070996. View

16.

Besla R, Penuel E, Del Rosario G, Cosino E, Myrta S, Dillon M . T cell-Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing. Cancer Immunol Res. 2023; 12(1):60-71. DOI: 10.1158/2326-6066.CIR-23-0072. View

17.

Pinter M, Pinato D, Ramadori P, Heikenwalder M . NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy. Clin Cancer Res. 2022; 29(3):513-520. PMC: 9890137. DOI: 10.1158/1078-0432.CCR-21-1258. View

18.

Yau T, Kang Y, Kim T, El-Khoueiry A, Santoro A, Sangro B . Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncol. 2020; 6(11):e204564. PMC: 7530824. DOI: 10.1001/jamaoncol.2020.4564. View

19.

Kudo M . Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2022; 11(4):592-596. PMC: 9396100. DOI: 10.21037/hbsn-22-143. View

20.

Rumgay H, Ferlay J, de Martel C, Georges D, Ibrahim A, Zheng R . Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer. 2021; 161:108-118. DOI: 10.1016/j.ejca.2021.11.023. View